Compare · MDLN vs NPCE
MDLN vs NPCE
Side-by-side comparison of Medline Inc. (MDLN) and Neuropace Inc. (NPCE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and NPCE operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $44.15B, about 82.3x NPCE ($536.6M).
- Over the past year, MDLN is down 17.1% and NPCE is up 20.5% - NPCE leads by 37.6 points.
- MDLN has been more active in the news (20 items in the past 4 weeks vs 14 for NPCE).
- MDLN has more recent analyst coverage (25 ratings vs 15 for NPCE).
- Company
- Medline Inc.
- Neuropace Inc.
- Price
- $33.80+0.58%
- $15.63-0.48%
- Market cap
- $44.15B
- $536.6M
- 1M return
- -19.55%
- -18.87%
- 1Y return
- -17.07%
- +20.51%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2021
- News (4w)
- 20
- 14
- Recent ratings
- 25
- 15
Neuropace Inc.
NeuroPace, Inc. operates as a medical device company in the United States. The company develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. Its RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,164,385,709 worth of shares (31,868,237 units at $36.54) and disposed of 1,887,801 shares (SEC Form 4)
- Director Healy Patrick J acquired 202,106 shares, increasing direct ownership by 15% to 1,387,921 units (SEC Form 4)
- Large owner Bx Mozart Ml-2 Holdco L.P. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Large owner Bcp 8 Holdings Mozart Manager L.L.C. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Medline's Prime Vendor model expands outside the United States
- Medline Inc. announces closing of upsized secondary offering of Class A common stock
- Medline announces participation in upcoming investor conferences
- MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Large owner Bx Mozart Ml-1 Holdco L.P. converted options into 11,348,698 shares and disposed of 11,348,698 units of Class B Common Stock (SEC Form 4)
Latest NPCE
- Director Huennekens R Scott was granted 2,890 shares (SEC Form 4)
- Director Fischer Frank M was granted 2,890 shares, increasing direct ownership by 0.49% to 598,067 units (SEC Form 4)
- Director Geiger Uri was granted 2,890 shares, increasing direct ownership by 19% to 17,748 units (SEC Form 4)
- Director Kumar Rakhi was granted 2,890 shares, increasing direct ownership by 15% to 22,050 units (SEC Form 4)
- Director Ryan Renee was granted 2,890 shares (SEC Form 4)
- Director Andrade Lisa was granted 2,890 shares (SEC Form 4)
- CHIEF EXECUTIVE OFFICER Becker Joel covered exercise/tax liability with 1,255 shares, decreasing direct ownership by 0.89% to 140,436 units (SEC Form 4) to satisfy withholding tax
- NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting
- NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care
- CHIEF EXECUTIVE OFFICER Becker Joel covered exercise/tax liability with 1,126 shares, decreasing direct ownership by 0.79% to 141,691 units (SEC Form 4) to cover taxes